103 related articles for article (PubMed ID: 3770033)
1. Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Cocconi G; Tonato M; Di Costanzo F; Bisagni G; Belsanti V; Buzzi F; Ceci G
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):761-4. PubMed ID: 3770033
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma.
Lluch A; Azagra P; Cervantes A; Muñoz M; Alberola V; Santabarbara P; García-Conde J
Oncology; 1994; 51(4):352-5. PubMed ID: 8208520
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Kucuk O; Shevrin DH; Pandya KJ; Bonomi PD
Am J Clin Oncol; 2000 Aug; 23(4):371-5. PubMed ID: 10955866
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and etoposide in chemotherapy-refractory advanced breast cancer.
Giaccone G; Donadio M; Ferrati P; Calciati A
Tumori; 1988 Apr; 74(2):191-3. PubMed ID: 3368973
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer.
Içli F; Günel N; Dinçol D; Karaoğuz H; Demirkazik A
J Surg Oncol; 1992 Aug; 50(4):251-3. PubMed ID: 1640710
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
Wallerstein R; Spitzer G; Dunphy F; Huan S; Hortobagyi G; Yau J; Buzdar A; Holmes F; Theriault R; Ewer M
J Clin Oncol; 1990 Nov; 8(11):1782-8. PubMed ID: 2121909
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
Lund B; Hansen OP; Hansen HH; Hansen M
Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of carboplatin and etoposide activity in pretreated breast cancer patients.
Viñolas N; Daniels M; Estapé J; Grau JJ; Palombo H; Solá C
Am J Clin Oncol; 1992 Apr; 15(2):160-2. PubMed ID: 1553906
[TBL] [Abstract][Full Text] [Related]
10. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of carboplatin and etoposide in metastatic breast cancer.
Crown J; Hakes T; Reichman B; Lebwohl D; Gilewski T; Surbone A; Currie V; Yao TJ; Hudis C; Seidman A
Cancer; 1993 Feb; 71(4):1254-7. PubMed ID: 8435802
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
13. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
14. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
15. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
[TBL] [Abstract][Full Text] [Related]
16. Platinum/oral etoposide therapy in non-small cell lung cancer.
Furuse K
Oncology; 1992; 49 Suppl 1():63-9; discussion 70. PubMed ID: 1323814
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
19. Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer.
Remick SC; Chmura M; Bromberg C; Sporn J; Healey B; Hilstro J; DeConti RC; Horton J; Ruckdeschel JC; Harper GR
Am J Clin Oncol; 1996 Apr; 19(2):125-31. PubMed ID: 8610634
[TBL] [Abstract][Full Text] [Related]
20. Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study.
Fried G; Stein ME; Haim N
Med Pediatr Oncol; 2000 Jan; 34(1):10-3. PubMed ID: 10611578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
